Mergers & Acquisitions
By The Online Investor Staff, updated Wed., Apr. 24, 2:51 PM
Slide #74. Century Therapeutics — Clade Therapeutics, Inc.
Acquirer: |
Century Therapeutics (NASDAQ:IPSC) |
Acquiree: |
Clade Therapeutics, Inc. |
Details: |
Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory diseases, today announced plans to expand clinical development for its lead program, CNTY-101, a CD19-targeting iNK cell therapy, into additional autoimmune disease indications. CNTY-101 is currently being evaluated in a clinical trial in B-cell malignancies (ELiPSE-1) as well as a planned clinical trial in systemic lupus erythematosus (SLE) (CALiPSO-1), which is on track to be initiated in the first half of 2024. Century plans to pursue additional autoimmune disease indication regulatory filings in 2024. Century's increased research and development activities in autoimmune diseases are further supported by a $60 million private placement of its common stock to certain institutional investors. Concurrently, Century announced pipeline and platform enhancements through the acquisition of Clade Therapeutics, Inc. ("Clade"), a privately-held biotech company focused on discovering and delivering engineerable, off-the-shelf, scalable, and consistent stem cell-based medicines, with a focus on iPSC-derived _ T cells. The acquisition brings additional iPSC-focused pipeline programs and technology to Century spanning across cancer and autoimmune diseases. |
Century Therapeutics is a biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. Co.'s primary product candidate, CNTY-101, is an allogeneic, chimeric antigen receptors (CAR)-induce pluripotent stem cell-derived (iPSC-derived) natural killer (iNK) cell therapy that has been engineered to express CD19 CAR, soluble IL-15, an epidermal growth factor receptor safety switch, and also contains gene edits needed to incorporate Allo-Evasion technology. CNTY-103 is Co.'s main product candidate targeting a solid tumor.
IPSC SEC Filing Email Alerts Service
Open the IPSC Page at The Online Investor »
Company Name: |
Century Therapeutics Inc |
Website: |
www.centurytx.com |
Sector: |
Biotechnology |
Number of ETFs Holding IPSC: |
13 |
Total Market Value Held by ETFs: |
$6.00M |
Total Market Capitalization: |
$198.00M |
% of Market Cap. Held by ETFs: |
3.03% |
|
Open the IPSC Page at The Online Investor (in a new window) »
|
April 24, 2024 2:51 PM Eastern
Strong Buy (3.71 out of 4)
68th percentile
|
|